The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1405
December 10, 2012
View Complete Issue         Table of Contents 2019 
Aclidinium Bromide (Tudorza Pressair) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Aclidinium Bromide (Tudorza Pressair) for COPD
December 10, 2012 (Issue: 1405)
The FDA has approved aclidinium bromide (Tudorza Pressair – Forest), an orally-inhaled long-acting anticholinergic, for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Aclidinium Bromide (Tudorza Pressair) for COPD
Article code: 1405b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.